Anne Kirsti Blystad

  • Consultant
  • +47 22 93 50 36
 

Publications 2016

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Publications 2011

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-9
DOI 10.1093/annonc/mdr385, PubMed 21926399

Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G (2011)
Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy
Eur J Haematol, 87 (6), 494-502
DOI 10.1111/j.1600-0609.2011.01681.x, PubMed 21752097

Publications 2004

Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D, Torlakovic E (2004)
Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma
Am J Clin Pathol, 121 (1), 34-42
DOI 10.1309/TNKL-7GDC-66R9-WPV5, PubMed 14750238

Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G (2004)
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy
Br J Haematol, 125 (5), 605-12
DOI 10.1111/j.1365-2141.2004.04951.x, PubMed 15147376

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Publications 2002

Holte H, Smeland S, Blystad AK, Kvaløy S, Hammerstrøm J, Tjønnfjord GE (2002)
[Intensive chemotherapy in Burkitt's lymphoma and aggressive non-Hodgkin's lymphoma]
Tidsskr Nor Laegeforen, 122 (4), 364-9
PubMed 11915663

Publications 2001

Blystad AK, Enblad G, Kvaløy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001)
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas
Bone Marrow Transplant, 27 (7), 711-6
DOI 10.1038/sj.bmt.1702867, PubMed 11360110

Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
Bone Marrow Transplant, 28 (9), 849-57
DOI 10.1038/sj.bmt.1703244, PubMed 11781645

Blystad AK, Torlakovic E, Holte H, Kvaløy S, Lenschow E, Kvalheim G (2001)
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD
Cytotherapy, 3 (4), 295-305
DOI 10.1080/146532401317070934, PubMed 12171718

Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH, European Bone Marrow Transplant Lymphoma Working Party (2001)
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry
J Clin Oncol, 19 (3), 727-35
DOI 10.1200/JCO.2001.19.3.727, PubMed 11157024

Publications 1999

Josefsen D, Blomhoff HK, Lømo J, Blystad AK, Smeland EB (1999)
Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells
Exp Hematol, 27 (4), 642-53
DOI 10.1016/S0301-472X(98)00073-3, PubMed 10210322

Publications 1997

Lien HH, Blomlie V, Blystad AK, Holte H, Langholm R, Kvaløy S (1997)
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement
Acta Radiol, 38 (5), 896-902
PubMed 9332252

Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH (1997)
High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Bone Marrow Transplant, 20 (9), 745-52
DOI 10.1038/sj.bmt.1700963, PubMed 9384476

May 12, 2004 Page visits: 860